References
- Mhatre R., Herman E. I., Huidobro A., Waravdekar V. The Possible Relationship Between Metabolism and Cardiac Toxicity of Daunomycin and Related Compounds. J. Pharmcol. Exp. Ther. (1971); 178: 216
- Woodman R. J., Cysyik R. L., Kiine I., Gan M., Venditti J. M. Enhancement of the Effectiveness of Daunorubicin (NSC 82151) or Adriamcin (NSC‐123127) Against Early Mouse L1210 Leukemia with ICRF 159 (NSC‐129943). Cancer Chemotherapy Reports (1975); 59: 689
- Wang G. M., Finch M., Trevan D. Razoxane‐Protected, Daunomycin‐Induced Deaths in BDF1 Mice. (1980), Submission
- Herman E., Ardalan B., Bier C., Waravdekar V., Krop S. Reduction of Daunorubic in Lethality and Myocardial Cellular Alterations by Pretreatment with ICRF‐187 in Syrian Golden Hamsters. Cancer Treat. Rep. (1979); 63: 89
- Loveless H., Arena E., Felsted R. L., Bachur N. R. Comparative Mammalian Metabolism of Adriamycin and Daun‐Orubicin. Cancer Res. (1978); 38: 593
- Bachur N. R., Gee M. Daunomycin Metabolism by Rat Tissue Preparation. J. Pharm. Exper. Therap. (1971); 177: 567
- Herman E. H., Mhatre R. M., Chadwick D. P. Modifications of Some of the Toxic Effects of Daunomycin (NSC‐82151) b6 pretreatment with the Antineoplastic Agent ICRF 159 (NSC‐129943). Tox. Applied Pharm. (1974); 27: 517
- Langslet A., Øye I., Lie S. Ø. Decreased Cardiac Toxicity of Adriamycin and Daunorubicin When Bound to DNA. Acta Pharmacol, et Toxicol. (1974); 35: 379
- Rosenoff S. H., Brooks E., Bostick F. Alterations of DNA Synthesis of Heart, Bone Marrow and G. I. Mucosa Induced by Adriamycin in Vivo: Relationship to Fatal Toxicity. Proc. Am. Assoc. Cancer Res. (1974); 15: 38
- Formelli F., Zedeck M. S., Sternberg S. S., Phillips F. S. Effects of Adriamycin on DNA Synthesis in Mouse and Rat Heart. Cancer Res. (1978); 38
- Herman E. H., Mhatre R. M., Lee I. P., Waravdekar V. S. Prevention of the Cardiotoxic Effects of Adriamycin and Daunomycin in the Isolated Dog Heart (36432). Proc. Soc. Biol. Med. (1972); 140: 234